WHEN HORMUZ BLEEDS, AYURVEDA HURTS
“When the Strait of Hormuz closes, it does not merely halt oil tankers — it silently disrupts the ghrita that lubricates Ayurvedic tablet presses, the sulphur that purifies Gandhaka Rasayana, the copper that carries electricity to the bhavana chamber, the fertiliser that feeds the herb farm, and the sesame oil that is Tila Taila itself. The war in the Persian Gulf is not happening to someone else. It is happening to us.”
SECTION 1 — THE BLINDSPOT: WHAT AYURVEDIC PRACTITIONERS DON’T SEE
Ask any Ayurvedic physician what threatens the future of the tradition, and you will receive a familiar litany. Deforestation. Adulteration of raw drugs. The decline of classical scholarship. The encroachment of biomedicine. Regulatory overreach. These are real concerns, and they deserve the sustained attention they receive. But there is a category of threat that almost nobody in Ayurvedic circles discusses — not in journals, not in conferences, not in the corridors of our teaching hospitals — and it may be the most consequential of all.
That threat is the petrochemical and industrial metal dependency of Ayurvedic manufacturing.
Every single Ayurvedic tablet that leaves a GMP-certified facility, every ointment dispensed from an Ayurvedic hospital pharmacy, every Arishta bottled and labelled for retail is, at multiple points in its production, touched by petroleum derivatives. The capsule shell, the tablet lubricant, the ointment base, the bottle, the blister pack, the transport fuel — these are not incidental features of modern manufacturing. They are structural necessities. And they are sourced, ultimately, from crude oil.
Similarly, three metals that Rasashastra regards as the pinnacle of therapeutic possibility — gold (Suvarna), silver (Rajata), and copper (Tamra) — are today the subject of a fierce global competition that Rasashastra texts could not have anticipated. That competition comes not from rival healing traditions but from the artificial intelligence industry, the electric vehicle sector, and the semiconductor manufacturing complex, all of which are consuming gold, silver, and copper at historically unprecedented rates.
And then there is sulphur — Gandhaka — which Rasashastra regards as an Uparasa of singular importance. Almost no practitioner who prescribes Gandhaka Rasayana knows, or thinks to ask, where the sulphur came from. The answer, in nearly every case, is a petroleum refinery. And the largest single regional source of pharmaceutical-grade sulphur in Asia is now at the epicentre of an active military conflict.
The war between the United States, Israel, and Iran that began on 28 February 2026 is, for most Ayurvedic practitioners, a geopolitical event — something to follow on the news, something to feel concerned about as citizens, but essentially unrelated to clinical practice. This article is an argument that this perception is wrong. The war in the Persian Gulf is disrupting Ayurveda’s supply chain right now, as you read this. It is raising the cost of your formulations, threatening the purity of your mineral preparations, and exposing a structural vulnerability in the tradition’s modern commercial form that two decades of GMP compliance and AYUSH policy documents have done nothing to address.
It is time the profession saw that thread — and began to think, honestly, about what it means.
SECTION 2 — OIL AND ITS HIDDEN FOOTPRINT IN AYURVEDIC MANUFACTURING
The Numbers That Should Unsettle Every Ayurvedic Manufacturer
India is, in energy terms, one of the most import-dependent large economies on earth. This is not a new problem, but it has become a dramatically worse one. India’s crude oil import dependence reached 88.6 to 89.4 percent of total consumption in financial year 2024–25 — an all-time record, and a figure that has risen in every single year for the past decade. Domestic crude oil production, meanwhile, fell 22.3 percent over the same period, dropping from 36.94 million tonnes in 2015–16 to 28.70 million tonnes in 2024–25. India’s proved crude reserves themselves declined 12 percent between 2014 and 2025. The trajectory is unambiguous and, absent a strategic reversal, points toward 92 percent import dependence by 2035 according to projections from the International Energy Agency and the Council on Foreign Relations.
India now imports approximately 243 million metric tonnes of crude oil annually — a volume that makes it the world’s third-largest crude importer and, as of 2024, the single largest driver of new global oil demand, having surpassed China in that year. The country’s petroleum import bill in FY 2024–25 exceeded fifteen trillion rupees.
These numbers matter to Ayurvedic manufacturers in ways that are rarely made explicit. Let us make them explicit now.
The Petroleum Footprint: From Bhavana to Blister Pack
Petroleum and its refined byproducts appear at virtually every stage of Ayurvedic pharmaceutical manufacturing. The following account is not exhaustive — it is illustrative, and it is already enough to demand a complete rethinking of how the industry understands its own material basis.
Petrolatum and Vaseline are residues of crude oil refining, highly purified for pharmaceutical use. They are the standard bases for external Ayurvedic preparations — ointments, nasal preparations (Nasya bases), wound treatments, and many topical Lepa formulations that have been adapted from classical practice into commercial forms. When crude oil prices rise, petrolatum prices follow. There is no herbal substitute that meets current GMP standards for ointment bases in modern manufacturing at scale.
Paraffin wax, another petroleum fraction, is used in tablet coating, capsule sealing, and as a protective layer on certain Bhasma-containing formulations to prevent atmospheric oxidation. The waxy coating on the tablet that reaches the patient’s hand is, in the overwhelming majority of cases, a petroleum derivative.
Liquid paraffin (mineral oil), derived from mid-distillate petroleum fractions, functions as both a lubricant in tablet pressing machinery and as the active constituent in certain oral laxative preparations — including some commercially marketed Ayurvedic digestive products. It is listed in the Indian Pharmacopoeia and is indispensable in modern tablet manufacturing.
Polyethylene glycol (PEG) is synthesised from ethylene oxide, which is itself derived from ethylene — a fundamental petrochemical. PEG is used as a binder and lubricant in tablet formulation, as a carrier in ointment bases, and as a solubility enhancer for herbal extracts. It is present in an extraordinary range of Ayurvedic commercial products.
Propylene glycol, another petroleum-derived compound, functions as a solvent for herbal extracts and as a humectant in Ayurvedic cosmeceutical creams. The herbal extract in the cream may be derived from Kumari or Chandana or Manjishtha — the carrier that stabilises and delivers it is a petrochemical.
Plastic packaging is the most visible and largest-volume petroleum dependency in Ayurvedic manufacturing. High-density polyethylene (HDPE), polyethylene terephthalate (PET), and polyvinyl chloride (PVC) are all derived from petrochemical feedstocks. Every Arishta bottle, every tablet strip, every powder sachet, every capsule blister, every syrup container that reaches an Ayurvedic pharmacy shelf arrived there in a petroleum-derived container. The notion of “natural Ayurvedic medicine” in a plastic bottle is, at minimum, a paradox that the profession has so far chosen not to examine.
LPG and piped gas are the workhorses of the Ayurvedic manufacturing process itself. Bhavana (trituration with liquid), Paka (heat-mediated preparation), Asava-Arishta fermentation chamber temperature regulation, Avaleha preparation, steam distillation of Arka — all of these classical processes, when conducted at commercial scale in modern GMP facilities, are powered by LPG or natural gas. Both are sourced from the same supply chains as crude oil.
Lubricating oils — for granulators, roller compactors, capsule-filling machines, fluid bed dryers, tablet punching machines — are petroleum derivatives. A modern GMP Ayurvedic facility cannot operate without them. When the engineering team orders machine lubricants, they are ordering refined petroleum products. This connection is rarely made in Ayurvedic institutional discourse, but it is structurally real.
Electricity itself, the silent energy infrastructure that powers every GMP Ayurvedic facility in India, is generated overwhelmingly from coal and petroleum. The automated bhavana machine runs on electricity. The cold chain that preserves temperature-sensitive raw materials runs on electricity. The quality control laboratory runs on electricity. The HVAC system that maintains GMP-compliant manufacturing environments runs on electricity. India’s grid remains profoundly fossil-fuel dependent.
The Industry’s Silence on This Dependency
What is striking is not the dependency itself — it is historically inevitable given the trajectory of pharmaceutical manufacturing globalisation — but the near-total absence of any institutional reckoning with it. AYUSH policy documents discuss raw material security in terms of medicinal plant conservation. CCRAS research priorities list drug standardisation, clinical trials, and pharmacognosy. The National Medicinal Plants Board concerns itself, appropriately, with cultivation and conservation. Nobody, to this author’s knowledge, has published a systematic analysis of Ayurvedic manufacturing’s petrochemical dependency and its implications for supply chain resilience.
The Hormuz crisis of 2026 is forcing that analysis into existence, whether the profession is ready for it or not.
SECTION 3 — THE THREE METALS: COPPER, SILVER, GOLD — AND THE GEOPOLITICAL SQUEEZE
Tamra, Rajata, Suvarna: The Classical Hierarchy
Rasashastra’s engagement with metals is not incidental to Ayurvedic philosophy — it is, in many respects, its most technically sophisticated expression. The discipline recognises that certain metals, properly purified and processed through Shodhana (detoxification) and Marana (incineration to Bhasma form), acquire therapeutic properties that herbal preparations cannot replicate. The Bhasma — reduced to ash, tested by traditional parameters of fineness, non-reconstitutability, and buoyancy — represents a centuries-developed technology of mineral medicine that has no equivalent in any other traditional system.
Copper (Tamra), silver (Rajata), and gold (Suvarna) occupy the highest tier of this system. Tamra Bhasma is indicated in liver disorders, anaemia, and skin diseases. Rajata Bhasma is prescribed in neurological conditions, cardiac debility, and wasting diseases — Kshaya, in classical nomenclature. Suvarna Bhasma is the crown of Rasashastra: Mahayogavahi, the supreme Rasayana, the rejuvenator that enhances the efficacy of every formulation it accompanies. Suvarna Prashan, the paediatric immunomodulatory ritual of administering gold-processed preparations to infants, has experienced a remarkable revival in recent decades.
These are living clinical realities, not museum pieces. And all three metals are now under resource pressure of a kind the tradition has never previously encountered.
Copper: The Metal That Powers Both Bhasma and the AI Revolution
Copper is, simultaneously, the metal of Tamra Bhasma, of Jala Dharana (the therapeutic practice of storing water in copper vessels, which has become a globally recognised wellness intervention), of Tuttha (copper sulphate) used in eye preparations and antiseptic compounds — and the most critically contested industrial metal of the twenty-first century.
The numbers are sobering. Copper prices are forecast to rise 12 to 20 percent over 2024 levels in 2025 alone, driven by a confluence of demand drivers that were simply not present even a decade ago. AI data centres require dramatically more copper per unit of computing capacity than conventional server infrastructure. Every electric vehicle contains approximately 83 kilograms of copper, compared to 23 kilograms in a conventional internal combustion vehicle. The global energy transition — solar panels, wind turbines, grid-scale battery storage — is copper-intensive in ways that are only beginning to be fully understood. And AI hardware, including the GPU clusters and power distribution systems that drive large language models and inference engines, is creating a new category of copper demand that did not exist at the turn of this century.
The result is a structural deficit. Mining capacity for copper cannot be expanded on the same timeline as demand. New copper mines take 10 to 15 years from discovery to production at scale. The world is, in effect, competing for a finite and slowly expandable supply of refined copper — and traditional medicine’s requirements, though small in global absolute terms, are competing in the same market.
For the Ayurvedic pharmacy that sources pharmaceutical-grade copper for Tamra Bhasma preparation, or the wellness brand that markets copper vessels as health products, the price trajectory is one-directional: upward, and for structural rather than cyclical reasons.
Silver: The Metal of Rajata Bhasma and the AI Chip
Silver’s situation is, if anything, more acute than copper’s. The metal occupies a unique and irreplaceable position in both classical Rasashastra and modern semiconductor manufacturing — a coincidence that creates a direct competition between two of the most different human knowledge traditions imaginable.
In Rasashastra, Rajata Bhasma is prepared through a meticulous process of Shodhana and repeated Marana, producing ultra-fine silver particles whose therapeutic identity is entirely distinct from metallic silver. The classical texts describe it as Hridya (cardiac tonic), Medhya (intellect-enhancing), and Rasayana — a rejuvenator appropriate for the debilitated, the aged, and the neurologically compromised. Rajata Jala — water stored in silver vessels — is a simpler therapeutic application with strong antimicrobial rationale. Silver foil (Vark) is used to coat prestigious compound formulations, lending them both aesthetic distinction and, classically, enhanced potency.
In the global economy, silver’s industrial demand hit a record 465.6 million ounces in 2024, according to the World Silver Survey published by the International Silver Institute in 2025. The dominant driver of this demand is AI hardware. Silver’s thermal conductivity of 429 watts per metre-kelvin is the highest of all metals — a property that makes it irreplaceable in high-performance semiconductor packaging, GPU and TPU internal connections, and the power distribution infrastructure of AI data centres. Standard server racks draw 10 to 15 kilowatts; AI racks require 60 to 130 kilowatts, creating enormous demands for silver in circuit breakers, relays, switchgear, and silver-plated copper busbars. Industrial demand for silver grew an estimated 7 percent in 2024 and is projected to grow a further 5 to 10 percent in 2025.
The supply picture is structurally concerning. Silver’s global supply has remained largely stagnant for nearly a decade. This is not a temporary anomaly — it reflects a mining sector that has not invested at the scale required to meet the demand transformation driven by electrification and artificial intelligence. The tension between record-breaking demand growth and a stagnant supply base is, by definition, a long-term price escalation driver.
For the Ayurvedic manufacturer preparing Rajata Bhasma or coating formulations with silver Vark, this means that the already expensive therapeutic tradition of Rasashastra is becoming more expensive at the same pace as the AI industry scales. These two realities are connected by a shared raw material — and the AI industry’s financial resources for procurement dwarf those of the Ayurvedic pharmaceutical sector by several orders of magnitude.
Gold: The Crown of Rasashastra Under Sustained Resource Pressure
Gold’s situation requires less elaboration because its price trajectory is already familiar to anyone paying attention to financial markets. What is less appreciated is the structural driver that is adding a new, powerful demand stream to an already historically elevated gold price.
In Rasashastra, Suvarna Bhasma is not merely an expensive formulation — it is, in the system’s own terms, a category-defining therapeutic agent. Its status as Mahayogavahi — the supreme potentiator, enhancing the action of every formulation it accompanies — makes it the reference point against which other Rasayana preparations are measured. Hiranyagarbha Pottali, Suvarna Sutashekhara Rasa, and the Suvarna-containing variants of classical formulations like Brahmi Vati represent the pinnacle of clinical Rasashastra in active use. Suvarna Prashan has, in the wellness economy, become a high-value paediatric service delivered by Ayurvedic practitioners across India and the diaspora.
All of this requires high-purity gold. And gold is now being consumed by the electronics industry at rates that the World Gold Council describes as accelerating. Technology demand for gold reached approximately 326 tonnes in 2024 — a 7 percent year-on-year increase. A typical smartphone contains 7 to 34 milligrams of gold; at 1.4 billion smartphones produced annually, the consumption is staggering before accounting for servers, AI accelerators, networking equipment, and industrial electronics. As AI hardware deployments, electric vehicle rollouts, solar installations, and grid infrastructure upgrades scale concurrently, all gold demand streams are expanding simultaneously.
The clinical consequence is one that many Ayurvedic physicians already observe but rarely articulate as a systemic issue: an authentic course of Suvarna Bhasma treatment, at genuine therapeutic dosage and quality, is priced out of reach for the vast majority of patients in India. This is not merely a matter of pharmaceutical economics — it is a therapeutic access failure with ethical dimensions that the profession has largely avoided confronting. The AI-driven demand for gold in electronics will deepen this inaccessibility. The patient who might have benefited from Suvarna Bhasma will instead receive the cheaper alternative — and the cheaper alternative is not Suvarna Bhasma.
SECTION 4 — SULPHUR: THE ELEMENT AYURVEDA REVERES AND INDUSTRY MONOPOLISES
Gandhaka in the Classical Tradition
Among the substances classified as Uparasa in the Rasashastra system, Gandhaka — sulphur — occupies a position of particular therapeutic importance and a distinctive philosophical identity. It is one of the few mineral substances whose purification process (Shodhana) is sufficiently well-documented across multiple classical texts — Rasa Ratna Samucchaya, Rasarnava, Anandakanda — that we can trace both the consistency and the variations in the tradition’s understanding of it.
Gandhaka Rasayana is, in everyday clinical Ayurveda, one of the most commonly prescribed Rasashastra formulations. It is not exotic, not rare in its prescription, and not restricted to specialist Rasashastra practitioners. It is recommended in Kushtha (a broad category encompassing skin diseases), Kandu (itching and dermatological inflammation), Jirnajvara (chronic and recurrent fevers), Viryakshaya (seminal debility), Agnimandya (impaired digestive and metabolic function), Grahani (chronic malabsorptive disorders), and Shula (abdominal colic). It functions additionally as a Rasayana — a rejuvenative agent — and is prescribed in the broader context of immune and constitutional strengthening.
Gandhaka Shodhana — the purification of raw sulphur — employs cow’s milk or ghee, and sometimes plant extracts including Eclipta alba, to transform elemental sulphur into a form that is physically more nebulous, more brittle, and pharmacochemically more suitable for therapeutic use. Research published in the Indian Journal of Pharmaceutical Sciences has confirmed that this traditional process produces physicochemical transformations in the sulphur — changes in colour, density, melting point, and the removal of toxic aromatic impurities — that are not replicated by standard industrial purification. In other words, Gandhaka Shodhana is not an alternative to chemical purification. It is a different process that achieves different, and in certain respects superior, endpoints for pharmaceutical use.
The sulphur that enters this process needs to be of appropriate purity. And that sulphur comes from a source that most Ayurvedic practitioners have never thought about.
The Industrial Source of Gandhaka: A Petroleum Refinery
Here is the irony that deserves to be stated plainly. Global sulphur supply is, in the modern economy, almost entirely a byproduct of petroleum refining and natural gas processing. Sulphur is present in crude oil and natural gas as an impurity. Environmental regulations globally require that refineries remove this sulphur before the fuel products can be sold — the result would otherwise be sulphur dioxide emissions of catastrophic scale. The removed sulphur is then processed, predominantly by the Claus process, into elemental sulphur — and that elemental sulphur enters global commodity markets.
The practical implication is this: the Gandhaka that a Rasashastra pharmacist purchases to prepare Gandhaka Rasayana came, in the overwhelming majority of cases, from an oil refinery. The tradition that positions itself as an alternative to industrial medicine is, at this specific and concrete point, entirely dependent on the industrial petroleum sector for one of its most important therapeutic minerals.
The geography of this dependency is equally important. Iran is one of the world’s largest sulphur producers, deriving its sulphur from the massive sour crude fields of Khuzestan province and the South Pars/North Dome natural gas field. Saudi Arabia and the UAE are also major producers. The Persian Gulf region as a whole is a dominant source of global sulphur supply — which means that the same conflict that is disrupting India’s crude oil imports is simultaneously disrupting the supply of pharmaceutical-grade sulphur for Ayurvedic and other traditional medicine manufacturing.
The agricultural fertiliser industry — the largest consumer of sulphur globally, using it in the production of superphosphate and ammonium sulphate fertilisers — competes intensely for this supply. India’s fertiliser industry, already under strain from the same geopolitical disruptions, has priority claims on available sulphur. Pharmaceutical-grade sulphur for Ayurvedic use is, in the supply chain hierarchy, a secondary consideration.
When sulphur supply tightens, manufacturers face a choice that has no good answer: pay the elevated price for pharmaceutical-grade material, substitute with lower-grade sulphur and accept quality risks, or suspend production. Each of these options carries consequences for the patient at the end of the therapeutic chain.
Quality as a Casualty of Supply Disruption
This point deserves emphasis because it connects a geopolitical event — a war 3,000 kilometres from Bengaluru — to a clinical outcome in an Ayurvedic hospital ward. Supply disruptions do not merely raise prices. They create incentives for substitution with inferior materials. In the context of Rasashastra preparations, where the therapeutic identity of the product is inseparable from the quality and purity of its mineral inputs, this substitution is not a commercial decision — it is a clinical one, with potential safety implications.
The classical texts are explicit: impure Gandhaka is toxic. The Shodhana process exists precisely because raw sulphur contains aromatic impurities that can cause systemic harm. A supply chain under stress, incentivising cost-cutting by manufacturers competing on price in a disrupted market, is a supply chain that is more likely to compromise on the quality of its sulphur inputs. The patient who receives Gandhaka Rasayana prepared from inadequately purified sulphur is not receiving the therapeutic agent that Rasashastra developed and validated over centuries. They are receiving something else — and in the absence of systematic testing and transparency, neither the prescribing physician nor the patient will know the difference.
SECTION 5 — THE CURRENT CRISIS: WHAT THE WAR IN THE PERSIAN GULF MEANS FOR AYURVEDA RIGHT NOW
Anatomy of the Bottleneck
The Strait of Hormuz is a geographical feature that most people know by name but whose dimensions are rarely appreciated. At its narrowest point, it is 21 nautical miles wide — a chokepoint through which, in the first quarter of 2025, approximately 20.1 million barrels per day of combined crude oil, condensate, and petroleum products transited daily, according to the US Energy Information Administration. This represents approximately 20 to 25 percent of the world’s entire seaborne oil trade, and roughly 20 percent of global liquefied natural gas supply, with the LNG flowing primarily from Qatar’s Ras Laffan facility and the UAE. There are, in practical terms, no alternative routes of comparable capacity. The pipeline alternatives that exist can handle only a fraction of the volume, and only for specific categories of crude and product.
On 28 February 2026, the United States and Israel began a series of military strikes against Iran targeting nuclear infrastructure, ballistic missile production facilities, and Iranian Revolutionary Guard Corps naval assets. Iran’s response included closing the Strait to commercial traffic, deploying sea mines, boarding and attacking merchant vessels, and launching attacks on Gulf Cooperation Council energy infrastructure. By March 4, Iranian forces had formally declared the Strait closed, and the threat of attack had prompted the majority of commercial shipping firms to suspend operations through the chokepoint regardless of any military escort provision.
The energy market response was immediate and extreme. On March 9, Brent crude surged past $115 per barrel — a 24 percent increase in a single session. By the end of March, the Brent price had increased approximately 65 percent, or $46 per barrel, over pre-conflict levels, recording the largest single monthly price rise in the history of global oil markets, according to the World Bank’s April 2026 Commodity Markets Outlook. QatarEnergy, the world’s largest LNG producer, declared force majeure on its Ras Laffan facility. Natural gas prices in Asia rose 54 percent and in Europe 63 percent in the week following the conflict’s escalation. The US, by contrast, saw natural gas prices rise only 7 percent — a reminder of how differently energy security distributes itself across geographies.
A conditional ceasefire agreed on April 7–8 did not reopen the Strait in any operationally meaningful sense. As of the time of writing, the Strait remains effectively closed to normal commercial traffic, with a US naval blockade of Iranian ports adding a further layer of disruption to the regional energy ecosystem.
India in the Eye of the Storm
For India, the consequences have been severe and are compounding. The country lost over 40 percent of its crude oil flows from the moment the Strait’s disruption became operationally effective — the fraction of India’s crude imports that typically transited the strait. Oil marketing companies — Indian Oil, Bharat Petroleum, Hindustan Petroleum — began bleeding losses of up to ₹1,000 crore per day as the government maintained pump prices at artificially suppressed levels to shield consumers from the immediate inflationary shock.
The macroeconomic damage has been rapid and multilayered. The rupee hit new all-time lows against the US dollar. Foreign institutional investors pulled more than $20 billion from Indian equities in the first four months of 2026 — already surpassing the previous full-year record for outflows. India’s GDP growth projection for FY 2026–27 has been revised downward to 6.7 percent from 7.7 percent by BMI/Fitch. Current forecasts from investment banks and rating agencies project Indian CPI inflation of 5 to 6 percent in Q2–Q3 2026 as the government eventually passes energy cost increases to consumers.
The specific vulnerabilities are more concentrated than the headline numbers suggest. India imports over 60 percent of its household LPG, with 90 percent of those imports transiting Hormuz. More than half of India’s LNG supply arrives from Qatar and the UAE through the same route. The government has issued a Natural Gas Control Order rationing supply, imposed customs duty exemptions on petrochemical products, and cut excise duties on motor fuels. It has also pursued bilateral diplomatic negotiations with Iran for safe passage of Indian-flagged vessels — an approach that has yielded limited and inconsistent results given the broader military and diplomatic context.
India has demonstrated some resilience through supply diversification — Russia has emerged as the single largest alternative crude supplier, leaning on the trading and logistics infrastructure built during the earlier Ukraine-related western sanctions period. But Russian crude requires longer shipping routes, commands a smaller discount than it did in 2022–23, and cannot fully substitute for the Gulf volumes lost to the Hormuz closure.
The Specific Impact on Ayurvedic Manufacturing: A Sector-by-Sector Analysis
Against this macroeconomic backdrop, what is happening — right now, in the financial year that Ayurvedic pharmaceutical companies are operating through — to the specific cost and supply chains of the industry?
LPG and process fuel costs are the most immediate and direct impact. Every Ayurvedic GMP facility that uses LPG for Paka, Avaleha preparation, Asava-Arishta fermentation temperature management, or steam generation has seen its energy cost escalate sharply. For a mid-sized manufacturer running multiple production lines, the LPG cost increase represents a significant margin compression that cannot be easily absorbed when selling prices are constrained by market competition and institutional purchasing frameworks.
Petroleum-derived excipient costs — petrolatum, liquid paraffin, PEG, propylene glycol — have risen in lockstep with crude prices. These are internationally priced commodities; when Brent crude rises 65 percent, the cost of petroleum-derived pharmaceutical excipients follows, typically with a lag of four to eight weeks as existing inventories are worked through. For manufacturers formulating ointments, semisolids, and topical preparations with high petrolatum or mineral oil content, this is a direct cost of goods increase.
Plastic packaging inflation is perhaps the broadest impact across the industry. HDPE, PET, and PVC packaging materials are petrochemical derivatives, and their prices track crude oil with relatively tight correlation. Every unit of packaged Ayurvedic product — tablet, capsule, liquid, powder, cream — has become more expensive to package. The cost increase is unit-level and cumulative across the entire product portfolio.
Sulphur supply and quality pressure is the impact that most directly threatens the integrity of Rasashastra formulations. As discussed in the previous section, Iranian sulphur exports — already disrupted by the conflict — constitute a meaningful fraction of Asia’s pharmaceutical-grade sulphur supply. Manufacturers who have not maintained buffer stocks or diversified their sulphur sourcing are facing both higher prices and quality uncertainty. The incentive to substitute with lower-grade material, in a cost-compressed operating environment, is significant.
Metal cost escalation for Rasashastra formulations is accelerating through the gold, silver, and copper price increases driven by both conflict-related safe-haven demand and the structural AI-driven industrial demand discussed in the previous section. A manufacturer of Suvarna Bhasma, already operating on thin margins due to the specialised nature of the preparation, faces a double pressure: higher raw material costs and, in some cases, difficulty sourcing high-purity gold in the current market.
The asymmetry of impact across the industry deserves explicit acknowledgment. Large, well-capitalised manufacturers — the Daburs, Himalayas, Patanjalis, Kottakkals, and Nagarjunas of the sector — have procurement buffers, long-term supplier contracts, and the financial capacity to absorb short-term cost shocks or pass them through gradually. It is the small and medium Ayurvedic manufacturer — the regional GMP unit, the hospital pharmacy, the teaching institution’s pharmacy department — that is most immediately and severely exposed. These are precisely the institutions most likely to be producing classical Rasashastra formulations with genuine quality commitment. The crisis disproportionately harms the most conscientious segment of the manufacturing sector.
SECTION 5B — THE EDIBLE OIL CRISIS: WHEN TAILA AND GHRITA BECOME UNAFFORDABLE
Sneha: The Therapeutic Medium That Holds the System Together
No other category of substance occupies as structurally central a position in Ayurvedic therapeutics as Sneha — fats and oils. The Charaka Samhita places Snehana (oleation therapy) among the foundational Samshodhana (purification) procedures. The Ashtanga Hridayam declares, without ambiguity, that of all oils, Tila Taila — sesame oil — is supreme. Ghrita — clarified butter from the cow — is elevated even beyond Taila in the hierarchy of therapeutic Snehas, described as possessing Sahasra Guna (a thousand virtues) upon appropriate preparation, and as the preeminent Rasayana vehicle, capable of carrying herb-derived intelligence into the deepest tissues.
These are not rhetorical distinctions. They have direct pharmaceutical consequences. The Taila Kalpana (medicated oil preparation) is one of Ayurveda’s most sophisticated dosage forms — a complex extraction technology in which active phytoconstituents are partitioned into an oil base through the Snehapaka process: three-component preparation using Kwatha (decoction), Kalka (herbal paste), and the base Sneha, heated together until the aqueous fraction is driven off and the oil retains the extracted active principles. The classical ratio — one part Kalka, four parts Sneha, sixteen parts Kwatha — is a precise pharmaceutical specification, not folklore.
Hundreds of named Taila formulations in the Ayurvedic pharmacopoeia use sesame oil (Tila Taila) as the mandatory default base. Mahanarayan Taila, Ksheerabala Taila, Bala Ashwagandhadi Taila, Sahacharadi Taila, Pinda Taila — these and scores of others specify sesame oil as the Sneha Dravya. Coconut oil (Narikela Taila) is the standard for certain Kerala-tradition formulations, particularly those used in Panchakarma. Castor oil (Eranda Taila) is specified for certain Vata-dominant and gynaecological formulations. Mustard oil (Sarshapa Taila) has its own regional therapeutic identity. Each is a specific pharmaceutical input — not an interchangeable commodity.
Ghrita preparations — the Ghrita Kalpanas — are equally irreplaceable. Brahmi Ghrita, Mahakalyanaka Ghrita, Panchagavya Ghrita, Triphala Ghrita, Shatavari Ghrita, Tiktaka Ghrita — these formulations use cow’s ghee as the Sneha base because the classical texts, and the pharmacological reasoning behind them, specify ghee as the vehicle for fat-soluble and lipid-mediated active principles that require deep tissue penetration. The Sneha Paka process for Ghrita follows the same three-component logic as Taila preparation.
These are, in short, the oil and fat foundations of the entire Ayurvedic pharmaceutical tradition. And they are now under a supply and price pressure that the tradition has never previously experienced at this scale.
India’s Edible Oil Crisis: The Numbers
India is the world’s largest importer of vegetable oils — a fact that, stated plainly, reveals an extraordinary strategic vulnerability for a nation with 1.4 billion people and the world’s second-largest agricultural land area. The country meets approximately 55 to 60 percent of its annual edible oil demand through imports, importing a total of 16.3 million tonnes in FY 2024–25. The annual edible oil import bill ran to approximately $19.2 billion in FY 2024 — around ₹1.6 lakh crore.
Palm oil dominates this import basket, accounting for approximately 57 to 60 percent of import volumes — roughly 7.5 to 9 million tonnes annually, sourced overwhelmingly from Indonesia and Malaysia. Soybean oil accounts for roughly 23 percent, with soybean oil imports hitting a record 5.47 million tonnes in 2024–25. Sunflower oil accounts for approximately 16 percent.
The relevance to Ayurveda is not direct — the tradition does not use refined palm oil, soybean oil, or industrial sunflower oil as therapeutic Snehas. The Charaka Samhita did not prescribe Refined Bleached Deodorised Palmolein. The relevance is indirect but structurally powerful: the overall cooking oil price in India is dominated by palm oil import prices. When palm oil prices rise — as they did by approximately 30 percent in 2025 — the reference price for all edible oils in India rises. Domestic sesame oil, which the Ayurvedic farmer grew and the pharmacy purchased in a relatively bounded regional market, is now priced in relation to a global commodity market driven by Indonesian plantation yields, Malaysian export levies, and rupee-dollar movements.
The result: sesame oil prices are subject to upward pressure not because sesame cultivation has failed but because the entire edible oil price architecture in India is indexed to imported palm oil. For an Ayurvedic pharmacy purchasing sesame oil for Taila preparation, the cost has been rising — not dramatically, but steadily, and as part of a pattern that has no structural reversal in sight given India’s inability to achieve edible oil self-sufficiency.
The Ghrita Crisis: Cattle, Feed, and the Fertiliser Connection
The situation for ghee — specifically the cow’s ghee that Ayurvedic Ghrita Kalpanas require — is even more structurally complex, because it connects the petroleum crisis, the fertiliser crisis, and the agricultural production system in a single chain of dependency.
Cattle in modern India are not maintained on grass alone. Commercial dairy farming, and even semi-commercial mixed farming, relies on manufactured cattle feed — concentrates composed of de-oiled rice bran, cottonseed cake, groundnut cake, maize, soybean meal, mineral supplements, and bypass protein. These feed inputs are themselves agricultural commodities, the prices of which are directly affected by fertiliser costs, fuel costs (for harvesting and transport), and the overall inflation in the agricultural input chain.
In May 2026, both Amul and Mother Dairy raised milk prices by ₹2 per litre, explicitly citing increased cattle feed costs, higher fuel costs for transportation, and rising packaging material prices as the drivers. The organisations stated that costs had increased substantially over the prior year and that only a portion of the increase was being passed on to consumers to protect farmers’ livelihoods. This was not a minor price adjustment — it was a signal of structural cost pressure moving through the dairy supply chain.
The fertiliser link is the most consequential and the least understood. India’s total fertiliser requirement in 2024–25 was approximately 649 lakh metric tonnes. Domestic production covered 465 lakh metric tonnes; the shortfall of 160 lakh metric tonnes was met through imports — overwhelmingly from the Persian Gulf. Of total urea imports, approximately 70 percent came from Gulf countries including Oman, Saudi Arabia, Qatar, and the UAE. Over 60 percent of India’s DAP (diammonium phosphate) requirement is imported, with the majority coming from the Gulf region. Potash imports from Saudi Arabia account for approximately 42 percent of India’s requirements.
The Hormuz crisis has disrupted all of these supply chains simultaneously. The global fertiliser price index rose 15 percent in the first half of 2025 according to the World Bank, with DAP recording a 23 percent increase and triple superphosphate a staggering 43 percent increase. UNCTAD has warned explicitly that the near-paralysis of Hormuz shipping is driving up fertiliser and energy costs, threatening global food security. The outbreak of the 2026 conflict led Iranian fertiliser producers to halt urea and ammonia output. Saudi Arabia raised urea prices to $450 per tonne FOB, up significantly from $402 previously.
The cascade operates as follows: fertiliser supply disruption → higher input costs for agricultural fodder crops (maize, soybean, groundnut) → higher cattle feed prices → higher cost of maintaining dairy animals → higher milk procurement prices → higher ghee production costs → higher Ghrita Kalpana formulation costs. This cascade is not hypothetical. It is active, demonstrable, and measurable — and it connects a war in the Persian Gulf directly to the cost of a bottle of Brahmi Ghrita or Mahakalyanaka Ghrita on an Ayurvedic hospital pharmacy shelf.
The implication for the tradition’s therapeutic practice deserves explicit statement: Ghrita Kalpana preparations, which the classical tradition regards as some of its most potent and Rasayana-grade formulations, are becoming more expensive to produce at precisely the same time as the metals, minerals, and energy inputs of the rest of the Ayurvedic manufacturing sector are also escalating. The compounding of multiple supply chain pressures on a sector with thin margins and limited price elasticity is a recipe for quality compromise — and it is happening now.
The Sesame Question: Is Ayurveda’s Primary Oil Secure?
Sesame (Tila) is not a Gulf-dependent crop. India is itself a significant sesame producer, and the oil is not on the front line of the Hormuz-driven import crisis. This might appear to offer some comfort. It does not offer as much as it appears to.
Sesame cultivation in India is characterised by high climate-sensitivity, dependence on rain-fed conditions in dryland farming areas, and susceptibility to price volatility driven by export demand from China, South Korea, and the United States. Sesame seed prices into India ranged from approximately $1.50 to $2.35 per kilogram in 2023 and 2024 — a 57 percent price range within a single two-year period. This is not a stable commodity price environment for pharmaceutical base oil procurement.
The deeper structural issue is that sesame cultivation in India is not systematically organised for pharmaceutical-grade supply. The sesame oil that enters the food market, the export stream, and the Ayurvedic pharmaceutical supply chain is largely the same product — undifferentiated, variably processed, and without the kind of quality-certification infrastructure that pharmaceutical-grade procurement requires. An Ayurvedic manufacturer requiring cold-pressed, unrefined, pesticide-free sesame oil of consistent fatty acid profile for classical Taila Kalpana is purchasing from a supply chain that was not designed to provide it.
Fertiliser costs affect sesame cultivation directly. Sesame is traditionally grown as a low-input crop — it does not require high fertilisation and can tolerate poor soils. But as competing crops become more fertiliser-intensive and as input costs rise generally across the agricultural sector, the economics of sesame cultivation relative to alternative crops shifts. When fertiliser price inflation makes high-yield, heavily fertilised crops like cotton, maize, and soybean relatively more profitable per acre, farmers may shift acreage away from sesame, reducing the supply available to Ayurvedic manufacturers.
This is not a crisis in the same acute sense as the Hormuz disruption. But it is a slow-moving structural pressure that operates on the same underlying logic: Ayurveda’s primary therapeutic oil base is a climate-sensitive, price-volatile, quality-undifferentiated commodity whose supply to pharmaceutical manufacturers is not systematically secured.
SECTION 5C — THE FERTILISER CRISIS AND THE HERB FARM: WHAT THE VAIDYA NEVER THINKS ABOUT
The Wild vs. Cultivated Divide: A Sector in Transition
When an Ayurvedic practitioner prescribes Ashwagandha, Shatavari, Guduchi, or Triphala, they almost certainly do not pause to consider whether the raw material in the formulation was cultivated or wild-harvested — and if cultivated, what fertilisers and pesticides were used in its production. This is an understandable lacuna in clinical thinking, but it represents a significant gap in the profession’s grasp of its own supply chain.
The reality is both more complex and more concerning than most practitioners appreciate. Data from the IBEF and various national surveys indicate that approximately 70 to 80 percent of India’s medicinal plant raw material was wild-harvested through most of the twentieth century. The National Medicinal Plants Board (NMPB) was established precisely because this wild-harvest dependency was recognised as ecologically unsustainable. The ‘All India Trade Survey of Prioritised Medicinal Plants, 2019’ documented a 50 percent increase in demand for high-value medicinal plants alongside a 26 percent decline in availability — a demand-supply scissors that has since been widened by the global Ayurvedic wellness boom, the COVID-19-driven surge in immunomodulatory herb demand, and the AYUSH export promotion agenda.
Of the 800 or so species that constitute the commercially significant Ayurvedic pharmacopoeia, approximately 200 — 25 percent — face overharvest-driven extinction risk. Critically endangered, endangered, vulnerable, and near-threatened medicinal plant species now number 65 within the commercially traded category. Among the at-risk species are several that Ayurvedic practitioners use routinely without any awareness of their ecological precarity: Kutki (Picrorhiza kurroa), Jatamansi (Nardostachys jatamansi), Kuth (Saussurea costus), Atis (Aconitum heterophyllum), and Salam Mishri (Orchis latifolia), among others.
The shift toward cultivation has been real but incomplete. By the early 2020s, cultivation’s share of the commercially traded raw material had risen from the historic 20–30 percent to approximately 50 percent, driven by the expansion of high-volume single-species herbs like Psyllium (Isabgol), Holy Basil (Tulsi), Ashwagandha, and Mint that are amenable to commercial cultivation. But for the complex, multi-species, classical Ayurvedic formulations — Chyawanprash, Dashamoola preparations, Sapta Dhatu-based Rasayana formulations — the raw material mix continues to include a significant fraction of wild-harvested species, particularly for roots, bark, and rhizomes of species that are difficult or uneconomic to cultivate at scale.
The Fertiliser-Herb Farm Connection
Here is the connection that very few people in Ayurvedic discourse have articulated, and which this article is obliged to make explicit: the medicinal plants that are cultivated in India — Ashwagandha in Rajasthan and Madhya Pradesh, Shatavari across the Deccan plateau, Guduchi along Karnataka and Maharashtra’s agricultural margins, Brahmi in wetland cultivation, Shankhapushpi in open-field cultivation in Gujarat and Rajasthan — are, in the overwhelming majority of cases, grown using conventional, chemically-fertilised, pesticide-treated agriculture.
The scale of this chemical dependency is rarely acknowledged. India’s total fertiliser consumption in 2024–25 was approximately 649 lakh metric tonnes — a figure that includes consumption on every category of commercial crop, including medicinal and aromatic plants where farmers have adopted cultivation methods. There is no large-scale evidence base for the claim that medicinal plant cultivation in India is predominantly organic — quite the contrary. The National Medicinal Plants Board’s own documentation acknowledges that cultivation of medicinal plants under the National Mission on Medicinal Plants (NMMP) is incentivised toward conventional agriculture, and that organic certification is rare outside the premium and export-oriented supply chains.
The fertiliser price escalation driven by the Hormuz crisis feeds directly into medicinal plant cultivation costs. DAP prices rose 23 percent in the first half of 2025; urea prices rose 15 percent. For a farmer growing Ashwagandha in Rajasthan or Shatavari in Karnataka on a commercial basis, these input cost increases are not abstract — they are direct reductions in margin that create pressure either to reduce fertilisation (affecting yield and quality) or to pass costs on to the raw material traders who supply Ayurvedic manufacturers.
The cascade continues: higher fertiliser costs → higher farm-gate prices for cultivated medicinal plants → higher raw material procurement costs for Ayurvedic manufacturers → higher formulation costs → higher consumer prices or compressed manufacturer margins, or both. This cascade is operating simultaneously with the petroleum excipient cost pressure and the LPG cost escalation described in Section 2. The cumulative effect on the cost structure of Ayurvedic manufacturing is severe.
The Pesticide Reality in Ayurvedic Raw Materials
The fertiliser question connects to the equally important pesticide question, which the profession has also preferred not to examine with the honesty it demands.
Cultivated medicinal plants in India — including most of the commercially important species used in mainstream Ayurvedic formulations — are treated with pesticides as a routine agricultural practice. There is no credible sector-wide evidence that pesticide use in medicinal plant cultivation is systematically lower than in conventional food crops. The incentive structure points in the opposite direction: medicinal plants are, in most cases, sold on the basis of appearance and price rather than chemical analysis, and the inspection infrastructure for pesticide residue testing in medicinal plant raw materials is inadequate.
Heavy metal contamination — from soil, water, and agricultural inputs — is an additional quality parameter that receives more attention in the research literature than it does in routine quality control. The confluence of environmental degradation, contaminated irrigation water, and agricultural chemical use creates a quality risk profile for cultivated Ayurvedic raw materials that is poorly understood and largely invisible to the prescribing physician.
The irony is stark. The tradition that has, since antiquity, specified the collection of drugs from specific ecosystems at specific times, by practitioners with specific qualifications (the Dravyaguna tradition’s emphasis on pariksha — examination — of raw materials), is today operating in a procurement environment where most raw materials come through anonymous commodity supply chains, are minimally tested, and may carry chemical residues incompatible with the tradition’s own pharmaceutical specifications.
The Organic Fraction: Small, Valuable, Vulnerable
India does have a certified organic medicinal plant sector. As of 2024, India had approximately 7.3 million hectares under organic certification including aromatic and medicinal plants, ranking second globally in organic agricultural land and first in total number of organic producers according to APEDA data. Several premium export-oriented Ayurvedic brands — both domestic and international — have invested in certified organic supply chains for key species.
But this certified organic fraction is a small minority of total Ayurvedic raw material production. And it is, structurally, the most expensive and most price-sensitive component of the supply chain. When fertiliser prices rise, the relative cost advantage of organic farming — which substitutes organic inputs, crop rotation, and biological controls for chemical inputs — narrows or reverses in the short term. Certified organic farmers face their own cost pressures from fuel (for transport and processing), labour, and certification compliance. The premium commanded by organic-certified raw material in the Ayurvedic supply chain is, for many manufacturers, simply not a procurement priority — particularly in a cost-compressed environment.
The honest conclusion is this: most Ayurvedic formulations sold in India today — including many sold under branding that evokes traditional, natural, and pure production — are made from raw materials produced with synthetic fertilisers and pesticides, processed with petroleum-derived excipients, packaged in petrochemical containers, and transported in diesel-powered vehicles. The gap between the tradition’s self-representation and its actual material reality is wider, and more consequential, than the profession has been willing to acknowledge. The current crisis has the potential to widen that gap further — or, if the profession responds with genuine strategic clarity, to begin closing it.
SECTION 6 — THE DEEPER STRUCTURAL PROBLEM: AYURVEDA’S INDUSTRIAL CONTRADICTION
“Natural Medicine” on a Petrochemical Scaffold
There is an irony at the centre of contemporary Ayurvedic practice that this article has been circling and must now name directly.
The modern, commercial, AYUSH-promoted, GMP-compliant Ayurveda that presents itself to the public as a natural alternative to industrial pharmaceutical medicine is, in its manufacturing infrastructure, a creature of the petroleum industry. It exists on a petrochemical scaffold. The tablet cannot be pressed without mineral oil lubricant. The ointment cannot be formulated without a petrolatum base. The product cannot reach the consumer without a plastic bottle. The production facility cannot operate without LPG. The excipients are hydrocarbons. The packaging is polymer. The cold chain runs on diesel.
This is not a criticism of the therapeutic validity of Ayurvedic preparations. The Rasa, the Guna, the Vipaka, the Virya of Triphala or Ashwagandha or Guduchi are not altered by the petrochemical container they inhabit. But the claim — implicit in much of Ayurveda’s contemporary branding and explicit in its institutional discourse — that the tradition represents a fundamentally different, naturally grounded relationship with healing materials is compromised by this dependency.
The more important point is not philosophical but strategic. A tradition that does not acknowledge its own material dependencies cannot manage those dependencies. The Hormuz crisis has revealed, abruptly and at scale, what a more honest institutional discourse would have been engaging with for the past two decades: that Ayurveda’s supply chain is deeply globalised, deeply fossil-fuel dependent, and deeply vulnerable to geopolitical shocks in the Middle East.
The Metals Squeeze: Traditional Medicine in Competition with the Digital Economy
The competition between Rasashastra and the semiconductor industry for gold, silver, and copper is not a metaphor. It is a concrete economic reality with a clear winner and a clear loser.
The global semiconductor industry’s revenues are projected to reach $800 billion in 2025, growing at 17.6 percent year-on-year. By 2025, AI chips drive approximately 20 percent of the global semiconductor market. The metals needed for these chips — copper, gold, silver, and rare earth elements — are simultaneously geopolitical pressure points and supply chain bottlenecks. The financial resources available to TSMC, Nvidia, Samsung, and Intel for procurement of these metals are unlimited relative to those available to any Ayurvedic pharmaceutical manufacturer.
When the World Gold Council reports that technology demand for gold grew 7 percent in 2024, and when AI hardware scaling is described as generating forecast double-digit growth in electronics gold demand for 2025 and beyond, the implication for Suvarna Bhasma is straightforward: the metal that Rasashastra requires is being consumed at accelerating rates by an industry with incomparably greater procurement power, and the price consequence falls on the Ayurvedic pharmaceutical sector and, ultimately, on the patient.
This is, to reiterate, not a crisis of the tradition’s intellectual validity. Suvarna Bhasma remains, by its own therapeutic epistemology, what it has always been. The crisis is one of access — a progressive repricing of the tradition’s most valued therapeutic materials out of the reach of ordinary clinical practice.
The Structural Failure of Domestic Energy Policy
The underlying context for all of the above is a domestic energy policy failure that India’s political discourse has been unwilling to confront with the honesty it requires.
India’s domestic crude oil production has fallen 22.3 percent over the last decade. Proved crude reserves declined 12 percent between 2014 and 2025. Natural gas reserves fell nearly 25 percent over the same period. Despite the government’s opening of previously restricted offshore areas for exploration in 2022, and despite incentive structures including lower royalty rates and zero revenue-sharing requirements for new entrants, domestic production continues to decline as ageing oil fields see sustained output falls. India is on a trajectory toward 92 percent import dependence for crude oil by 2035.
A nation that imports 89 percent of its crude oil, that hosts the world’s largest traditional medicine system, and that has committed to making AYUSH a global health resource — this nation has not, apparently, connected its energy policy failure to its traditional medicine supply chain vulnerability. That connection is now being made, brutally, by a military conflict in the Persian Gulf.
SECTION 7 — WHAT LIES AHEAD: SCENARIOS AND STRATEGIC IMPERATIVES
Three Scenarios for the Next 24 Months
Scenario A: Short Conflict, Partial Resolution. The Strait reopens within six to nine months; oil prices stabilise in the $80–90 per barrel range as strategic petroleum reserve releases from IEA member nations — which have already released 400 million barrels — take effect and alternative routing through the East-West pipeline and Fujairah export terminal partially compensates for Hormuz volumes. In this scenario, Ayurvedic manufacturers absorb short-term cost spikes; some pass costs on to consumers in the form of MRP increases that are rarely reversed when conditions improve. Metal prices remain structurally elevated regardless of conflict resolution, due to AI/EV demand. The crisis passes as a “warning shot” — uncomfortable but brief — and the institutional lessons are not drawn.
Scenario B: Prolonged Disruption. The Strait remains effectively closed through 2026 and into early 2027. India’s inflation reaches the projected 5 to 6 percent range. LPG continues to be rationed. Government pressure on Ayurvedic manufacturers to hold prices creates a margin compression that disproportionately affects small manufacturers. Sulphur quality deteriorates in the supply chain as cost-cutting accelerates. Some small GMP Ayurvedic manufacturers exit the market. Adulteration and substitution in Rasashastra formulations increases — not through criminal intent but through the quiet, undisclosed substitution of inferior materials under economic stress. The tradition’s quality base erodes silently.
Scenario C: Structural Transformation. This is not a prediction but an aspiration — a description of what a strategically self-aware Ayurvedic sector would do in response to the crisis, whether the conflict is short or prolonged.
What the Profession Must Do
The strategic imperatives that follow are offered not as policy recommendations to government bodies — though they are relevant to AYUSH policy — but as institutional and professional obligations that the Ayurvedic sector should assume for itself.
First: Acknowledge the dependency. The most fundamental step is epistemic. Ayurvedic professional bodies, journal editors, manufacturers’ associations, and institutional leaders must stop pretending that the tradition’s commercial form operates outside industrial supply chains. This pretence is not innocence — it is the institutional equivalent of the blindspot described in this article’s opening section, and it has real consequences.
Second: Demand transparent supply chain labelling. Which excipients in a given Ayurvedic formulation are petroleum-derived? Which metals were sourced from which refiners? GMP regulations require disclosure of excipients in formulation documentation — this information should be made visible to prescribing physicians and, eventually, to consumers. A tradition committed to transparency in its knowledge claims should not be opaque about its material inputs.
Third: Invest in domestic sulphur processing infrastructure. India should not be importing pharmaceutical-grade sulphur from Iran or Saudi Arabia for the preparation of Gandhaka Rasayana. The domestic petroleum refining sector — IOC, BPCL, HPCL, Reliance — produces sulphur as a byproduct in quantities that could supply the entire Ayurvedic pharmaceutical sector many times over. The missing link is a processing and quality certification infrastructure that converts industrial sulphur byproduct into pharmaceutical-grade Gandhaka. This is a solvable problem, and it is a problem that nobody has invested in solving because nobody in the institutional Ayurvedic sector has acknowledged that the problem exists.
Fourth: Develop plant-based and biodegradable packaging alternatives at scale. Research institutions affiliated with AYUSH, ICAR, and the IITs have the capability to develop viable alternatives to petrochemical packaging for Ayurvedic products. The commercial incentive is now present — both for ecological positioning and for supply chain resilience. This is not a counsel of perfection; it is a recognition that the crisis has created a strategic opportunity for genuine innovation.
Fifth: Reconsider the mythology of scale. The insistence on GMP mass production as the standard model for Ayurvedic manufacturing has created the petrochemical dependency this article describes. Hospital pharmacy-level production using traditional methods — clay vessels, wood fire, organic raw materials, small-batch preparation — is, paradoxically, more resilient in the face of geopolitical supply disruption than a state-of-the-art GMP facility running on LPG and packaging into PET bottles. This does not mean that all Ayurvedic manufacturing should revert to pre-industrial methods. It does mean that the institutional celebration of scale as inherently superior needs to be interrogated.
Sixth: Monitor commodity markets as part of institutional risk management. Ayurvedic manufacturers and the institutional bodies that regulate them should treat Brent crude futures, silver spot prices, copper LME rates, and sulphur commodity indices as routine business intelligence inputs. The Treasurer of a mid-sized Ayurvedic manufacturer should know what the three-month copper forward price is, and why it matters to the company’s Tamra Bhasma production costs. This is not exotic financial sophistication — it is basic supply chain management that the industry has not yet internalised.
Seventh: Establish strategic raw material reserves for Rasashastra institutions. Teaching hospitals and quality manufacturers of Rasashastra formulations should maintain buffer stocks of gold, silver, copper, and pharmaceutical-grade sulphur equivalent to at least six to twelve months of production requirements. In a supply chain environment that is demonstrably vulnerable to geopolitical disruption, this is not financial imprudence — it is therapeutic responsibility.
SECTION 8 — A REFLECTION FOR THE VAIDYA: SYSTEMIC THINKING AS DHARMA
The classical Vaidya was not merely a clinician. The tradition’s texts describe the ideal physician as a figure of broad knowledge — familiar not only with the properties of drugs and the nature of diseases but with the seasons, the geography, the social conditions, and the material realities of the world in which healing takes place. The Charaka Samhita’s description of the physician of good conduct encompasses an attentiveness to context — to the patient’s Desha, Kala, and Bala, but also to the conditions that shape the availability and quality of therapeutic materials. The ideal Vaidya, in other words, was a systemic thinker.
The modern Ayurvedic practitioner operates in a context of extraordinary complexity — a global supply chain, a geopolitical order under stress, a technology industry competing for the same raw materials as the healing tradition, and a petrochemical dependency that is invisible to most clinical eyes. The temptation, understandable and human, is to treat this complexity as someone else’s responsibility — the manufacturer’s problem, the government’s problem, the AYUSH ministry’s problem. The practitioner’s role, in this view, is to prescribe; others will ensure that what is prescribed is available, affordable, and genuine.
This is an abdication that the tradition’s own epistemology does not support. If Nidana — the investigation of causation — is a core clinical discipline, then the same investigative commitment should apply to the conditions of practice itself. What are the upstream causes of a patient’s inability to access Suvarna Bhasma? What are the upstream causes of Gandhaka Rasayana prepared from substandard sulphur reaching a prescription? What are the upstream causes of rising Bhasma costs that force patients toward substitute treatments of lower therapeutic specificity? These are questions with answers — answers that lead, if followed honestly, to a petroleum refinery in the Persian Gulf, an AI data centre in Arizona, and a military conflict over a 21-mile-wide strait.
Ignoring the supply chain is not neutrality. When a rural patient or an urban consumer suffers from adulterated Bhasma or unavailable Gandhaka Rasayana because of a war 3,000 kilometres from their home, the consequences fall most heavily on those who can least afford the alternatives. The practitioner who does not see this connection is not innocent of it — they are simply not looking.
The Ayurvedic tradition has survived — and more than survived, flourished — through centuries of political upheaval, material scarcity, and civilisational disruption. It has demonstrated a capacity for adaptation that its critics frequently underestimate. But adaptation requires clear-sightedness. It requires the willingness to see the tradition as it actually is, not as we would prefer it to be — naturalised, self-sufficient, insulated from the crude transactions of industrial modernity.
The Strait of Hormuz and the bhavana kund are not separate worlds. The oil tanker that cannot pass through a 21-mile chokepoint in the Persian Gulf is connected, by an invisible but structurally real thread of industrial modernity, to the Gandhaka Rasayana bottle on the Ayurvedic physician’s shelf. The GPU cluster consuming silver in a data centre in Oregon is connected, by the same logic of global commodity markets, to the silver foil on a Rajata Bhasma preparation in a Kottakkal pharmacy.
Seeing these connections is not pessimism. It is the beginning of genuine strategic thought. And genuine strategic thought, applied with the tradition’s own epistemological rigour, is what the moment requires.
STATISTICAL APPENDIX
| Data Point | Figure | Source |
|---|---|---|
| PETROLEUM & ENERGY | ||
| India crude import dependence, FY 2024–25 | 88.6–89.4% (all-time record) | PPAC / OilPrice.com, Feb 2026 |
| India domestic crude production decline (decade) | −22.3% (28.70 MT, FY 2024–25) | Dataful.in, April 2026 |
| India annual crude imports | 243.22 MT | Provisional FY 2024–25 |
| India proved crude reserves decline (2014–2025) | −12% (762 MT → 672 MT) | Ministry of Petroleum |
| India natural gas reserves decline (2014–2025) | −25% | Ministry of Petroleum |
| India crude import dependence projection, 2035 | 92% | IEA / CFR |
| HORMUZ CRISIS | ||
| Hormuz daily oil flow (pre-crisis, Q1 2025) | 20.1 million barrels/day | US EIA |
| Brent crude surge on March 9, 2026 | Past $115/barrel; +24% single session | MarketMinute / OilPrice.com |
| Brent crude surge by end-March 2026 | +65% ($46/barrel); largest monthly rise ever recorded | World Bank, April 2026 Commodity Markets Outlook |
| India crude flows lost since Hormuz closure | >40% | OilPrice.com, May 2026 |
| India oil marketing company losses | Up to ₹1,000 crore/day | OilPrice.com, May 2026 |
| Freight rates for oil tankers since Feb 2026 | +90% | UNCTAD, April 2026 |
| Foreign investor equity outflows, India, Jan–Apr 2026 | >$20 billion (exceeded full-year 2025 record) | Government of India data |
| India GDP growth forecast, FY 2026–27 | 6.7% (revised from 7.7%) | BMI/Fitch |
| India CPI inflation forecast, Q2–Q3 2026 | 5–6% | Investment banks / rating agencies |
| India household LPG via Hormuz | >90% of LPG imports | ORF, March 2026 |
| Asia natural gas price increase post-conflict | +54% | CRS, March 2026 |
| METALS & AI | ||
| Silver electronics/electrical demand, 2024 | Record 465.6 million oz | Silver Institute, World Silver Survey 2025 |
| Industrial silver demand growth, 2024 | +7% | International Silver Institute |
| Industrial silver demand growth projection, 2025 | +5–10% | Sectoral forecasts |
| Silver thermal conductivity | 429 W/m·K (highest of all metals) | Materials science data |
| Technology demand for gold, 2024 | ~326 tonnes (+7% YoY) | World Gold Council |
| Copper price forecast increase, 2025 | +12–20% over 2024 levels | Market analysis |
| Worldwide semiconductor revenue, 2025 | $800 billion (+17.6% YoY) | IDC |
| AI chips as share of global semiconductor market, 2025 | ~20% | Market analysis |
| AI rack power draw vs. standard rack | 60–130 kW vs. 10–15 kW | Dell’Oro Group / Nlyte, 2024–25 |
| EDIBLE OILS & GHRITA | ||
| India total vegetable oil imports, FY 2024–25 | 16.3 million tonnes | SEA of India |
| India vegetable oil import bill, FY 2024 | $19.2 billion (~₹1.6 lakh crore) | DFPD, 2024 |
| India edible oil import dependence | ~55–60% of annual consumption | NITI Aayog / SEA |
| Palm oil share of India’s vegetable oil imports | 57–60% (Indonesia, Malaysia) | SEA / GAPKI, 2024 |
| India soybean oil imports, FY 2024–25 | Record 5.47 million tonnes | SEA of India |
| India annual edible oil consumption | 25–26 million tonnes | NITI Aayog, 2024 |
| Amul / Mother Dairy milk price hike, May 2026 | ₹2/litre (cattle feed, fuel, packaging cited) | GCMMF / media reports |
| FERTILISERS & HERB FARMING | ||
| India total fertiliser requirement, 2024–25 | 649.43 lakh MT | Ministry of Chemicals & Fertilisers |
| India domestic fertiliser production, 2024–25 | 465.45 lakh MT | Ministry of Chemicals & Fertilisers |
| India fertiliser imports, 2024–25 | 160.29 lakh MT | Ministry of Chemicals & Fertilisers |
| India urea imports from Gulf countries | ~70% of total urea imports (Oman, Saudi, Qatar, UAE) | Ministry data |
| India DAP imports from Saudi Arabia | ~42% of total DAP imports | Ministry data / UNCTAD |
| Gulf region share of global urea exports | 36% (Iran + Qatar largest; India top importer) | IFPRI, April 2026 |
| Global fertiliser price index rise, H1 2025 | +15% (DAP +23%; TSP +43%) | World Bank |
| Hormuz disruption: global sulphur supply impact | −44% annually if fully closed | Kpler analysis |
| Hormuz disruption: global urea supply impact | −30% annually if fully closed | Kpler analysis |
| Iranian fertiliser producers post-conflict | Halted urea and ammonia output | IFPRI / Kpler, March 2026 |
| Saudi Arabia urea price increase (post-conflict) | $450/tonne FOB (from $402) | Market data |
| MEDICINAL PLANTS & SOURCING | ||
| Medicinal plants sourced from wild (20th century baseline) | 70–80% of total raw material | IBEF / Medwin Publishers |
| Wild plants collected by destructive methods | ~69% | IBEF survey |
| Increase in demand for high-value medicinal plants (since 2019) | +50% | All India Trade Survey of Prioritised Medicinal Plants, 2019 |
| Decline in medicinal plant availability (since 2019) | −26% | All India Trade Survey, 2019 |
| Critically endangered/threatened medicinal species (traded) | 65 species (10% of total commercially traded) | IBEF data |
| Cultivated share of medicinal plant raw material (current) | ~50% (up from 20–30% historically) | Medwin Publishers, 2024 |
| Species facing overharvest-driven extinction risk | ~200 of 800 traded species (25%) | Medwin Publishers / eco-agriculture data |
| India organic agricultural land (incl. aromatic/medicinal plants) | 7.3 million hectares (2nd globally) | APEDA, 2024 |
| India: total number of certified organic producers | 1st globally | APEDA, 2024 |
This article was researched and drafted with the assistance of Claude (Anthropic), an AI language model, in accordance with the author’s standing commitment to transparent AI collaboration disclosure. All analysis, framing, and interpretive judgments reflect the author’s intellectual position.
| *© Dr. Aakash Kembhavi | Ayurveda Unfiltered | June 2026* Reproduction with attribution permitted for non-commercial educational purposes. |
Share your thoughts in the comments below.
💬 Comments & Discussion